Trial intelligence / Profile preview

Fruquintinib plus standard chemotherapy for metastatic colorectal cancer

ChiCTR2200059280Phase 4Recruiting

Sponsor
Renmin Hospital of Wuhan University
Start
Apr 2021
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of fruquintinib in colorectal cancer (CRC), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: 1-year progression-free survival rate. Started Apr 2021; status: recruiting.

02

Drugs

fruquintinib
03

Conditions

colorectal cancer (CRC)

Beyond the preview

Go deeper on ChiCTR2200059280.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2200059280.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call